Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant intra-arterial cisplatin + pirarubicin after radical cystectomy for locally advanced bladder cancer
ChiCTR-TRC-09000359Phase 4Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cisplatin and pirarubicin in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: 2-year local progression-free survival, 3-year local progression-free survival and 5 more. Started Jan 2009; status: completed.
02
Drugs
cisplatinpirarubicin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR-TRC-09000359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000359.